Risk of Bleeding with Dabigatran in 2010–2011 Medicare Data

Lignende værker

• Comparing Stroke and Bleeding with Rivaroxaban and Dabigatran in Atrial Fibrillation: Analysis of the US Medicare Part D Data
  af: Hernandez, Inmaculada, et al.
  Udgivet: (2017)
• Higher Risk of Bleeding with Dabigatran in Atrial Fibrillation
  af: Hernandez, Inmaculada, et al.
  Udgivet: (2015)
• Anticoagulation Use and Clinical Outcomes Following Major Bleeding on Dabigatran or Warfarin in Atrial Fibrillation
  af: Hernandez, Inmaculada, et al.
  Udgivet: (2016)
• Real-World Direct Comparison of the Effectiveness and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Medicare Beneficiaries with Atrial Fibrillation
  af: Yang, Lanting, et al.
  Udgivet: (2020)
• Explaining Improved Use of High-Risk Medications in Medicare Between 2007 and 2011
  af: Driessen, Julia, et al.
  Udgivet: (2016)